Regorafenib in Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

March 9, 2022

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Regorafenib

Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).

Trial Locations (4)

14642

University of Rochester, Rochester

19111

Fox Chase Cancer Center, Philadelphia

27514

University of North Carolina at Chapel Hill, Chapel Hill

55901

Mayo Clinic, Rochester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Rochester

OTHER